BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32001290)

  • 1. Enhanced anti-tumor and anti-metastasis therapy for triple negative breast cancer by CD44 receptor-targeted hybrid self-delivery micelles.
    Yang Y; Long Y; Wang Y; Ren K; Li M; Zhang Z; Xiang B; He Q
    Int J Pharm; 2020 Mar; 577():119085. PubMed ID: 32001290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery.
    Yang Y; Zhao Y; Lan J; Kang Y; Zhang T; Ding Y; Zhang X; Lu L
    Int J Nanomedicine; 2018; 13():4361-4378. PubMed ID: 30100720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin.
    Wang J; Ma W; Guo Q; Li Y; Hu Z; Zhu Z; Wang X; Zhao Y; Chai X; Tu P
    Int J Nanomedicine; 2016; 11():5851-5870. PubMed ID: 27853369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
    Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
    Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facile strategy by hyaluronic acid functional carbon dot-doxorubicin nanoparticles for CD44 targeted drug delivery and enhanced breast cancer therapy.
    Li J; Li M; Tian L; Qiu Y; Yu Q; Wang X; Guo R; He Q
    Int J Pharm; 2020 Mar; 578():119122. PubMed ID: 32035259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyaluronic acid-coated PEI-PLGA nanoparticles mediated co-delivery of doxorubicin and miR-542-3p for triple negative breast cancer therapy.
    Wang S; Zhang J; Wang Y; Chen M
    Nanomedicine; 2016 Feb; 12(2):411-20. PubMed ID: 26711968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of hyaluronic acid-based polymersomes for doxorubicin delivery to metastatic breast cancer.
    Shahriari M; Taghdisi SM; Abnous K; Ramezani M; Alibolandi M
    Int J Pharm; 2019 Dec; 572():118835. PubMed ID: 31726198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.
    Wang Q; Zhong Y; Liu W; Wang Z; Gu L; Li X; Zheng J; Du H; Zhong Z; Xie F
    Drug Deliv; 2019 Dec; 26(1):12-22. PubMed ID: 30691317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitamin E-based micelles enhance the anticancer activity of doxorubicin.
    Danhier F; Kouhé TT; Duhem N; Ucakar B; Staub A; Draoui N; Feron O; Préat V
    Int J Pharm; 2014 Dec; 476(1-2):9-15. PubMed ID: 25245548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
    Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
    Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hyaluronic acid-based micelles and polyethylene glycol-based micelles on reversal of multidrug resistance and enhanced anticancer efficacy in vitro and in vivo.
    Wang J; Li Y; Wang L; Wang X; Tu P
    Drug Deliv; 2018 Nov; 25(1):330-340. PubMed ID: 29350064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppress orthotopic colon cancer and its metastasis through exact targeting and highly selective drug release by a smart nanomicelle.
    Zhu C; Zhang H; Li W; Luo L; Guo X; Wang Z; Kong F; Li Q; Yang J; Du Y; You J
    Biomaterials; 2018 Apr; 161():144-153. PubMed ID: 29421551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronic acid-capped compact silica-supported mesoporous titania nanoparticles for ligand-directed delivery of doxorubicin.
    Gupta B; Poudel BK; Ruttala HB; Regmi S; Pathak S; Gautam M; Jin SG; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2018 Oct; 80():364-377. PubMed ID: 30201431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
    Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
    J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy.
    Wang H; Zhang Y; Zeng X; Pei W; Fan R; Wang Y; Wang X; Li J
    Int J Nanomedicine; 2021; 16():2373-2388. PubMed ID: 33790555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
    Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
    Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
    [No Abstract]   [Full Text] [Related]  

  • 17. Tumor-specific penetrating peptides-functionalized hyaluronic acid-d-α-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers.
    Liang DS; Su HT; Liu YJ; Wang AT; Qi XR
    Biomaterials; 2015 Dec; 71():11-23. PubMed ID: 26310359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin.
    Qiu L; Qiao M; Chen Q; Tian C; Long M; Wang M; Li Z; Hu W; Li G; Cheng L; Cheng L; Hu H; Zhao X; Chen D
    Biomaterials; 2014 Dec; 35(37):9877-9887. PubMed ID: 25201738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation on vitamin e succinate based intelligent hyaluronic acid micelles for overcoming drug resistance and enhancing anticancer efficacy.
    Hou L; Tian C; Chen D; Yuan Y; Yan Y; Huang Q; Zhang H; Zhang Z
    Eur J Pharm Sci; 2019 Dec; 140():105071. PubMed ID: 31525433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Doxorubicin-Loaded Micelle Targeting MUC1: A Potential Therapeutic for MUC1 Triple Negative Breast Cancer Treatment.
    Khondee S; Chittasupho C; Tima S; Anuchapreeda S
    Curr Drug Deliv; 2018; 15(3):406-416. PubMed ID: 28707580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.